FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON - Spain 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2019
Criterium:Position:
Overall Score:800-900
Total Project Funding per Partner:> 1000
Total Number of Projects:800-900
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:900-1000
Total Number of Projects:700-800
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:400-500
Total Project Funding per Partner:500-600
Total Number of Projects:700-800
Networking Rank (Reputation):> 1000
Partner Constancy:800-900
Project Leadership Index:200-300
2012
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:69
Total Project Funding:> 1000
Networking Rank (Reputation):900-1000
Partner Constancy:46
Project Leadership Index:75
Diversity Index:60

Ranking timeline:

Project Participation Performance(2012-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 32
As coordinator: 2
As participant: 23
Sole participant: 7
Coordinator / Participant Ratio: 0.09*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2023 1.604.375 13.334.005 2.153.425 1 2
2022 172.932 41.935.193 2.343.303 1 4
2021 5.999.411 7.057.980 1.333.110 1 1
2020 0 12.958.834 83.312 2
2019 172.932 24.576.884 1.499.930 1 3
2018 148.875 17.102.522 1.768.124 1 3
2017 0 20.200.000 150.000 1
2016 147.750 7.113.779 495.729 1 1
2015 6.146.992 7.359.629 1.731.328 2 2
2014 0 1.730.700 1.730.700 1
2013 0 8.998.350 590.032 2
2012 233.705 150.000 383.705 1 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
UNIVERSITA DEGLI STUDI DI TORINO8
INSTITUT CATALA D'ONCOLOGIA6
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS6
EUROPEAN MOLECULAR BIOLOGY LABORATORY5
THE UNIVERSITY OF MANCHESTER5
ACADEMISCH ZIEKENHUIS GRONINGEN4
CHARITE UNIVERSITAETSMEDIZIN BERLIN4
DEUTSCHES KREBSFORSCHUNGSZENTRUM4
EUROPEAN CANCER PATIENT COALITION4
MASARYKOVA UNIVERZITA4
UNIVERSITY OF CAMBRIDGE4
BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM3
CENTRE DE REGULACIO GENOMICA3
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM3
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL3
FUNDACIO INSTITUT DE RECERCA BIOMEDICA3
INSTITUT CURIE3
INSTITUT GUSTAVE ROUSSY3
ISTITUTO EUROPEO DI ONCOLOGIA3
KATHOLIEKE UNIVERSITEIT LEUVEN3
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN3
ROYAL COLLEGE OF SURGEONS IN IRELAND3
STICHTING LYGATURE3
STICHTING VUMC3
VIB VZW3
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION2
BAYER2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
COMMISSARIAT A L'ENERGIE ATOMIQUE2
EATRIS ERIC2
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK2
EIBIR GEMEINNUTZIGE GMBH ZUR FORDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG2
EUROBIOIMAGING ERIC2
EUROPEAN INFRASTRUCTURE OF OPEN SCREENING PLATFORMS FOR CHEMICAL BIOLOGY EUROPEAN RESEARCH INFRASTUCTURE CONSORTIUM2
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI2
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON INSTITUT DE RECERCA2
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA DOCTOR JOSEP TRUETA2
FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON2
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA FUNDACION INCLIVA2
GENOME RESEARCH2
HOSPITAL UNIVERSITARIO DE FUENLABRADA2
INFRAFRONTIER2
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE2
INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO2
INSTRUCTERIC2
JANSSEN PHARMACEUTICA NV2
KAROLINSKA INSTITUTE2
MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH2
NOVARTIS PHARMA2
PINTAIL2
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM2
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL2
TAKEDA DEVELOPMENT CENTRE EUROPE2
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD2
TTOPSTART BV2
UNIVERSITAETSKLINIKUM AACHEN2
UNIVERSITAETSKLINIKUM HEIDELBERG2
UNIVERSITY COLLEGE DUBLIN2
UNIVERSITY OF HELSINKI2
UNIVERSITY OF NEWCASTLE UPON TYNE2
VRIJE UNIVERSITEIT BRUSSEL2
AALBORG UNIVERSITET1
ABBVIE INC1
AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA1
AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS1
AGENDIA NV1
ALBERT LUDWIGS UNIVERSITAET FREIBURG1
ALEXANDER FLEMING1
ALIRA HEALTH SL1
ALLEANZA CONTRO IL CANCRO1
ALTHAIA XARXA ASSISTENCIAL UNIVERSITARIA DE MANRESA FUNDACIO PRIVADA1
AMGEN1
ANAXOMICS BIOTECH S L1
ANTAROS MEDICAL AB1
ARIANA PHARMACEUTICALS1
ARTTIC INNOVATION1
ASTRAZENECA1
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA1
BARTS AND THE LONDON NHS TRUST1
BAYER PHARMA1
BELFAST HEALTH AND SOCIAL CARE TRUST1
BELGIAN NUCLEAR RESEARCH CENTRE1
BELGISCHE VERENIGING VOOR MEDISCHE ONCOLOGIE / SOCIETE BELGE D ONCOLOGIE MEDICALE/ BELGIAN SOCIETY OF MEDICAL ONCOLOGY1
BENGURION UNIVERSITY OF THE NEGEV1
BIOKERALTY RESEARCH INSTITUTE AIE1
BMD SOFTWARE LDA1
BUNDESAMT FUER STRAHLENSCHUTZ1
BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE1
CABALLERO LLANO CARMELO CESAR1
CANCER TRIALS IRELAND CLG1
CELGENE MANAGEMENT SARL1
CENTRE D'ETUDE ET DE RECHERCHES VETERINAIRES ET AGROCHIMIQUES1
CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD1
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE1
CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN1
CENTRE REGIONAL DE LUTTE CONTRE LE CANCER HENRI BECQUEREL ROUEN1
CENTRO HOSPITALAR DE SAO JOAO EPE1
CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY1
CHEMICELL1

Constancy:

Total number of partners: 388
Partner loyalty:
Frequent Partner: (> 2 projects): 96
Rare Partner: 292
Frequent / Rare Partner Ratio: 0.33

Project overview:

Start dateProjectacronymrolefundingpartners
2023-01-01CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE PREVENTABLEparticipant4.642.25015
2023-01-01Unraveling the Functional Complexity of Cancer Genomes through Chromosome Engineering MACHETEcoordinator1.604.3751
2023-01-01Open Consortium for Decentralized Medical Artificial Intelligence ODELIAparticipant8.691.75512
2022-11-01Data-driven cancer genome interpretation for personalised cancer treatment CGI-Clinicsparticipant9.257.50817
2022-09-01Providing cutting edge cancer research services across Europe canSERVparticipant14.866.44118
2022-09-01A European-wide foundation to accelerate Data-driven Cancer Research EOSC4Cancerparticipant7.814.54934
2022-06-01Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy I3LUNGparticipant9.996.69516
2022-03-28Multi-analyte liquid biopsy to monitor tumor genomic evolution and therapy response in advanced Prostate Cancer MultiLQB-PCcoordinator172.9321
2021-07-01Building a reproducible single-cell experimental workflow to capture tumour drug persistence PERSIST-SEQparticipant7.057.98016
2021-02-01Building Data Rich Clinical Trials CCE_DARTcoordinator5.999.41112
2020-09-01EURopeAn MEDical application and Radiation prOteCtion Concept: strategic research agenda aNd ROadmap interLinking to heaLth and digitisation aspects EURAMED rocc-n-rollparticipant1.959.17529
2020-01-01NGS diagnostics in 21st century oncology: the best, for all, at all times oncNGSparticipant10.999.65918
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00023
2019-05-01Co-targeting androgen receptor signalling and DNA damage repair for precision therapy in advanced prostate cancer AR-DDRcoordinator172.9321
2019-01-01CeLac and European consortium for a personalized medicine approach to Gastric Cancer LEGACyparticipant3.577.43111
2019-01-01EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine. EUCANCanparticipant5.999.45318
2018-07-01Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types. SYST-iMYCcoordinator148.8751
2018-02-01EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts EDIReXparticipant5.156.19919
2018-01-01Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions COLOSSUSparticipant5.996.36014
2018-01-01Systems Medicine of Metabolic-Signaling Networks: A New Concept for Breast Cancer Patient Stratification MESI-STRATparticipant5.949.96417
2017-01-01Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 HARMONYparticipant20.200.00053
2016-08-01Developing an anti-Myc cell-penetrating peptide for cancer treatment GBM-CPPcoordinator147.7501
2016-04-01Nanomedicine upscaling for early clinical phases of multimodal cancer therapy NoCanTherparticipant7.113.77912
2015-11-01Deciphering PI3K biology in health and disease Phdparticipant3.896.14813
2015-10-01Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) MoTriColorcoordinator5.996.99211
2015-07-01Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system. CSC-IScoordinator150.0001
2015-05-01Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities (MedBioinformatics) MedBioinformaticsparticipant3.463.4819
2014-05-01Pushing Myc inhibition towards the clinic MYCINHIBINCLINICparticipant1.730.7001
2013-12-01A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients MERCURICparticipant5.999.99513
2013-03-01WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients WINTHERparticipant2.998.35511
2012-12-01Targeting Cancer Stem Cells (CSC) for the development of more effective treatments to cure cancer patients ANTI-CSCparticipant150.0001
2012-06-01Role of Notch signaling pathway in Glioma Stem Cells Notch pathway in GSCcoordinator233.7051